RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an... It could offer benefit to millions of asthma and allergy patients.
- Mechanism
- Curator reviewed
RP01 is a novel immunotherapeutic that stimulates the immune system to produce antibodies against IgE (Immunoglobulin E), the key mediator of allergic reactions. The antibodies intercept and bind to IgE, thereby blocking it from causing allergic reactions. Such a mechanism of action is potentially effective regardless of the trigger, be it pollen, grass, dust mite, foodstuffs or pets.
- Primary indication
- Investigated for use/treatment in allergic reaction and asthma.Curator reviewed
Which companies are running trials of RP01, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account